Mumbai, April 26, 2018 – Mumbai’s renowned super specialty eye care Ojas Eye Hospital, offering unmatched eye care, has brought home Lumenis M22 Optimal Pulse Technology (OPT) for treatment of dry eyes. The latest eye care technology is a great revolutionary value addition to the ophthalmic applications especially for the treatment of dry eye.
Lumenis is the world’s largest energy-based medical device company and is renowned for technological breakthroughs ophthalmic lasers and a long list of industry gold standards.
M22 is the answer to a majority of eye inflammation treatments with OPT being the most advanced IPL technology, developed by World’s Largest Energy based medical device company, Lumenis. Designed and curated to deliver reliable, safe and enhanced physician and patient comfort, the M22 services will be available at Ojas Eye Hospitals at Bandra and Kandivali.
Commenting on the development, Dr. Niteen Dedhia, Medical Director, OJAS Eye Hospital said “M22 is a latest state of the art eye care technology. Most recent case studies and researches have showcased prevalence of dry eye among patients ranging across age groups. The introduction of M22 OPT technology will be a path breaker and a great relief to patients who have been prescribed to eye drops, the only available solution to treat dryness.”
Adding to his statement acclaimed eye surgeon, Dr. Dedhia also said that “Getting M22 OPT to our patients is a mission-driven consortium to bring the best in eye care to the people of Western India especially Mumbai. We are looking at this as a solution and step forward to our institution Ojas’ vision to be a Globally Recognized Eye Care Hospital known for its Distinctive Excellence & Patient Satisfaction.”
“Our path breaking technology will help address the growing dry eye disease among thousands of people,” said Mr. Dharmendra Mistry, Country Head of Lumenis India, “We are happy to partner with Dr. Niteen Dedhia, who is a veteran ophthalmologist and medical director at OJAS Eye Hospital. Entering in the western market is part of our expansion strategy ensuring the increasing number of patients who will be benefited from our latest OPT technology,” he said.
Meibomian Gland dysfunction (MGD) is one of the leading causes of dry eye disease (DED), affecting millions of people worldwide. Optimal pulse technology from Lumenis has emerged as the most effective alternative for patients, leading to significant improvement in ocular surface quality, gland function and dry eye symptoms.
The Lumenis M22 OPT is an excellent technology for treating eyelid inflammation. OPT is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombolysis. A major source of inflammation threatening the eyelids is then removed. It treats the root cause of the problem, provides immediate relief, a safe and comfortable, fast ‘lunch time treatment’ and improves the skin appearance too.
Studies show that humans generally blink about 22 times a minute. But when we concentrate on a computer screen or a smart phone or even while driving, the rate goes down to five or seven blinks per minute. If this tear film does not spread sufficiently across the eye, it can lead to dryness and irritation. Experts say dry eye affects millions of adults. The risk increases with advancing age.